Background: Elevated tumor marker levels have been reported in heart failure patients with left ventricular (LV) systolic dysfunction and enlargement. The levels of several tumor markers, including CA 125, CA 19-9, CA 15-3 and CEA, in rheumatic mitral stenotic patients were compared to the control group. Materials and Methods: Tumor markers were measured in 60 mitral stenotic patients and in 30 normal subjects who served as the control group. Mitral stenotic patients were classified into two categories of cardiac dysfunction based on the classification of the New York Heart Association (NYHA). Group I consisted of 31 patients in NYHA class 3–4 and group II of 29 patients in NYHA class 1–2. Echocardiographic examinations and invasive hemodynamic monitoring were performed in all patients. Results: Group I patients had decreased mitral valve area (p = 0.004) and higher left atrial diameter (p = 0.003) than group II patients. Right atrial, mean pulmonary artery and pulmonary capillary wedge pressures and transmitral gradient were higher in group I than in group II (p = 0.010, 0.0001, 0.0001 and 0.0001, respectively). CA 125 levels were statistically higher in mitral stenotic patient groups than in the control group (p < 0.0001). No statistically significant differences were shown for the other tumor markers. Group I patients had higher CA 125 levels compared to group II (p < 0.0001). Conclusion: Elevated CA 125 levels may be due to venous congestion and activation of peritoneal mesothelium or increased signal peptides.

1.
Bates SE: Clinical applications of serum tumor markers. Ann Intern Med 1991;115:623–638.
2.
Fritsche HA: Serum tumor markers for patient monitoring: A case-oriented approach illustrated with carcinoembryonic antigen. Clin Chem 1993;39:2431–2434.
3.
Fabris C, Falleti E, Pirisi M, Soardo G, Toniutto P, Vitulli D, Bortolotti N, Gonano F, Bartoli E: Non-specific increase of serum carbohydrate antigen 19–9 in patients with liver disease associated with increased circulating levels of adhesion molecules. Clin Chim Acta 1995;243:25–33.
4.
Wood WG, Werner A: CEA, TPA and CA 125 levels in different patient groups with benign and malignant disease. Arztl Lab 1984;30:309–315.
5.
Cases A, Filella X, Molina R, Ballesta AM, Lopez-Pedret J, Revert L: Tumor markers in chronic renal failure and hemodialysis patients. Nephron 1991;57:183–186.
6.
Collazos J: Clinical and laboratory evolution of CA 19–9 in cirrhotic patients. Eur J Med 1992;1:215–218.
7.
Kenemans P, Yedema CA, Bon GG: CA 125 in gynecological pathology: A review. Eur J Obstet Gynecol Reprod Biol 1993;49:115–124.
8.
Van der Burg ME, Lammes FB, Verweij J: CA 125 in ovarian cancer. Neth J Med 1992;40:36–51.
9.
Hopman EH, Helmerhorst TJ, Bonfrer JM, Ten Bokkel Huinink WW: Highly elevated serum CA 125 levels in a patient with cardiac failure. Eur J Obstet Gynecol Reprod Biol 1993;48:71–73.
10.
Nägele H, Bahlo M, Klapdor R, Schaeperkoetter D, Rödiger W: CA 125 and its relation to cardiac function. Am Heart J 1999;137:1044–1049.
11.
Seo T, Ikeda Y, Onaka H: Usefulness of serum CA 125 measurement for monitoring pericardial effusion. Jpn Circ J 1993;57:489–494.
12.
Toshihiko S, Megumi U, Takahiro H: Serum CA 125 measurement is useful in three cases with pericardial effusions. Kokyu To Junkan 1993;41:389–392.
13.
Apel RL, Fernandes BJ: Malignant lymphoma presenting with an elevated serum CA 125 level. Pathol Lab Med 1995;119:373–376.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.